Citizens Maintains Market Outperform Rating on Iovance, Raises Target to $12
Citizens raised its price target to $12 per share from $8 while maintaining its Market Outperform rating on Iovance Biotherapeutics.
Related stories
Microsoft Restores Outlook and Teams After Global Outage
Microsoft says service to Outlook and Teams has been restored after a global outage.
M impact | EQUITY | Nov 14, 2026, 07:23 AM UTC
Procter & Gamble’s St. Louis Operation Marks 100 Years
A Q&A discusses the operation’s history, AI and Cascade dishwasher pods.
M impact | EQUITY | Nov 14, 2026, 07:17 AM UTC
Microsoft Restores Services After Global Outage
Microsoft said services had fully recovered across Teams, Outlook, Copilot and other applications, ending an outage that disrupted online communications for businesses and governme
M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC
Microsoft Says All Services Restored After Global Outage
Microsoft said all services were restored after a global outage.
M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC
Microsoft says outage issue addressed and remaining service restored
Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions.
M impact | EQUITY | Nov 14, 2026, 06:37 AM UTC
Microsoft Completes Outage Fix, Restores Service to Remaining Customers
Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions.
L impact | EQUITY | Nov 14, 2026, 06:37 AM UTC